Sanjivani Paranteral Ltd

Sanjivani Paranteral Ltd, a micro-cap player in the Pharmaceuticals & Biotechnology sector, has been downgraded from a Hold to a Sell rating as of 1 April 2026. Despite demonstrating robust financial metrics and operational efficiency, the stock’s significant underperformance relative to the broader market and valuation concerns have prompted a reassessment of its investment appeal.

Sanjivani Paranteral Ltd, a micro-cap player in the Pharmaceuticals & Biotechnology sector, has seen its investment rating upgraded from Sell to Hold as of 30 March 2026. This change reflects a marked improvement in valuation metrics, financial trends, and quality parameters, despite recent underperformance relative to the broader market. The company’s current Mojo Score stands at 50.0, signalling a cautious but positive outlook for investors.

For the third consecutive session, Sanjivani Paranteral Ltd has seen its share price decline, culminating in a fresh 52-week low of Rs 133 on 30 Mar 2026. This marks a near 50% drop from its 52-week high of Rs 268.8, underscoring a sustained period of selling pressure despite some positive financial indicators.

Sanjivani Paranteral Ltd is rated 'Sell' by MarketsMOJO, with this rating last updated on 24 March 2026. However, the analysis and financial metrics discussed here reflect the stock's current position as of 30 March 2026, providing investors with an up-to-date view of the company’s performance and outlook.

For the second consecutive session, Sanjivani Paranteral Ltd closed lower, slipping to a fresh 52-week low of Rs 141 on 27 Mar 2026. This decline extends the stock’s recent downward momentum, with a 7.17% loss over the past two days despite an intraday high of Rs 154.7 today.

For the fifth consecutive session, Sanjivani Paranteral Ltd closed lower, breaching its 52-week low at Rs 142.7 on 25 Mar 2026, marking a significant 44.26% decline over the past year despite the broader market's modest losses.

Sanjivani Paranteral Ltd has witnessed a notable shift in its valuation parameters, moving from a fair to an attractive rating, driven primarily by its price-to-earnings (P/E) and price-to-book value (P/BV) ratios. Despite recent share price declines, the company’s valuation now presents a compelling case for investors seeking exposure in the Pharmaceuticals & Biotechnology sector, especially when contrasted with its peers and historical benchmarks.

For the third consecutive session, Sanjivani Paranteral Ltd has seen its share price decline, culminating in a fresh 52-week low of Rs 145.6 on 23 Mar 2026. This marks a significant 44.72% drop over the past year, far outpacing the broader Sensex's 4.97% decline during the same period.

Sanjivani Paranteral Ltd, a micro-cap player in the Pharmaceuticals & Biotechnology sector, recorded a new 52-week low of Rs.146.3 today, marking a significant decline in its stock price amid broader market movements and sectoral pressures.

Sanjivani Paranteral Ltd has seen its investment rating upgraded from Sell to Hold, reflecting improved valuation metrics and robust financial trends despite recent share price weakness. The upgrade follows a comprehensive reassessment across quality, valuation, financial performance, and technical indicators, signalling a more balanced outlook for this micro-cap pharmaceutical player.

Sanjivani Paranteral Ltd has seen a notable shift in its valuation parameters, moving from a fair to an attractive rating, driven primarily by changes in its price-to-earnings and price-to-book value ratios. Despite recent share price declines, the company’s valuation now presents a more compelling case relative to its historical averages and peer group, prompting a reassessment of its investment appeal within the Pharmaceuticals & Biotechnology sector.

Sanjivani Paranteral Ltd’s shares declined sharply to a new 52-week low of Rs.153 on 17 Mar 2026, marking a significant downturn for the pharmaceuticals and biotechnology micro-cap. The stock has underperformed its sector and broader market indices amid a sustained negative trend over recent weeks.

Sanjivani Paranteral Ltd’s shares declined to a fresh 52-week low of Rs.155 on 13 Mar 2026, marking a significant downturn amid broader market weakness. The stock has now recorded a three-day consecutive fall, shedding 6.75% over this period, underlining persistent pressures within the Pharmaceuticals & Biotechnology sector.

Sanjivani Paranteral Ltd is rated Sell by MarketsMOJO, with this rating last updated on 23 February 2026. However, all fundamentals, returns, and financial metrics discussed here reflect the stock’s current position as of 12 March 2026, providing investors with the latest comprehensive analysis.

Sanjivani Paranteral Ltd has experienced a notable shift in its valuation parameters, moving from an expensive to a fair valuation grade as of late February 2026. This change reflects evolving market perceptions amid a challenging price performance, with the stock down 7.46% on the day and a year-to-date decline of 25.3%, contrasting with broader market gains. Investors are now reassessing the company’s price attractiveness relative to its historical averages and peer group within the Pharmaceuticals & Biotechnology sector.

Sanjivani Paranteral Ltd is rated Sell by MarketsMOJO, with this rating last updated on 23 February 2026. However, the analysis and financial metrics discussed here reflect the stock’s current position as of 28 February 2026, providing investors with the latest insights into the company’s performance and outlook.